Published in Intensive Care Med on April 24, 2012
Prevalence of skin problems and leg ulceration in a sample of young injecting drug users. Harm Reduct J (2014) 0.98
Anthrax: A disease of biowarfare and public health importance. World J Clin Cases (2015) 0.97
Low-incidence, high-consequence pathogens. Emerg Infect Dis (2014) 0.93
Bacillus anthracis cell wall peptidoglycan but not lethal or edema toxins produces changes consistent with disseminated intravascular coagulation in a rat model. J Infect Dis (2013) 0.90
Bacillus anthracis, virulence factors, PCR, and interpretation of results. Virulence (2013) 0.89
B. anthracis edema toxin increases cAMP levels and inhibits phenylephrine-stimulated contraction in a rat aortic ring model. Am J Physiol Heart Circ Physiol (2013) 0.88
Two anthrax cases with soft tissue infection, severe oedema and sepsis in Danish heroin users. BMC Infect Dis (2013) 0.88
Bacillus anthracis edema factor substrate specificity: evidence for new modes of action. Toxins (Basel) (2012) 0.87
Anthrax lethal factor as an immune target in humans and transgenic mice and the impact of HLA polymorphism on CD4+ T cell immunity. PLoS Pathog (2014) 0.86
Raxibacumab: potential role in the treatment of inhalational anthrax. Infect Drug Resist (2014) 0.85
B. anthracis associated cardiovascular dysfunction and shock: the potential contribution of both non-toxin and toxin components. BMC Med (2013) 0.85
Injectional anthrax infection due to heroin use induces strong immunological memory. J Infect (2014) 0.81
An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis. Expert Opin Investig Drugs (2015) 0.80
Molecular characterization of Bacillus anthracis directly from patients' eschar and beef in an anthrax outbreak in Jiangsu Province, China, 2012. Am J Trop Med Hyg (2014) 0.80
Different Roles of N-Terminal and C-Terminal Domains in Calmodulin for Activation of Bacillus anthracis Edema Factor. Toxins (Basel) (2015) 0.78
Anti-infective immunoadhesins from plants. Plant Biotechnol J (2015) 0.78
Year in review in Intensive Care Medicine 2012. II: Pneumonia and infection, sepsis, coagulation, hemodynamics, cardiovascular and microcirculation, critical care organization, imaging, ethics and legal issues. Intensive Care Med (2013) 0.78
Channel-forming bacterial toxins in biosensing and macromolecule delivery. Toxins (Basel) (2014) 0.77
A case of fatal gastrointestinal anthrax in north eastern iran. Case Rep Infect Dis (2015) 0.77
The Ins and Outs of Anthrax Toxin. Toxins (Basel) (2016) 0.77
Effects of 39 Compounds on Calmodulin-Regulated Adenylyl Cyclases AC1 and Bacillus anthracis Edema Factor. PLoS One (2015) 0.77
Severe systemic Bacillus anthracis infection in an intravenous drug user. BMJ Case Rep (2014) 0.76
Crossing of the epithelial barriers by Bacillus anthracis: the Known and the Unknown. Front Microbiol (2015) 0.75
A novel multiplex PCR discriminates Bacillus anthracis and its genetically related strains from other Bacillus cereus group species. PLoS One (2015) 0.75
Alternative pre-approved and novel therapies for the treatment of anthrax. BMC Infect Dis (2016) 0.75
Whole genome protein microarrays for serum profiling of immunodominant antigens of Bacillus anthracis. Front Microbiol (2015) 0.75
Anthrax infection in an intravenous drug user. Intensive Care Med (2012) 0.75
Periorbital cellulitis due to cutaneous anthrax. Int Ophthalmol (2015) 0.75
First Autochthonous Coinfected Anthrax in an Immunocompetent Patient. Case Rep Med (2015) 0.75
Protective-antigen (PA) based anthrax vaccines confer protection against inhalation anthrax by precluding the establishment of a systemic infection. Hum Vaccin Immunother (2013) 0.75
Studies on respiratory infection. I. The influence of particle size on respiratory infection with anthrax spores. J Hyg (Lond) (1953) 12.95
Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis (2001) 11.73
Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA (2002) 10.40
The Sverdlovsk anthrax outbreak of 1979. Science (1994) 10.29
Anthrax. Annu Rev Microbiol (2001) 9.69
Anthrax. N Engl J Med (1999) 8.89
Identification of the cellular receptor for anthrax toxin. Nature (2001) 8.78
Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR Morb Mortal Wkly Rep (2001) 6.49
Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A (1993) 5.39
Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis (2002) 5.23
Biological warfare. A historical perspective. JAMA (1997) 4.10
Raxibacumab for the treatment of inhalational anthrax. N Engl J Med (2009) 3.91
Update: Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR Morb Mortal Wkly Rep (2001) 3.53
Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol Aspects Med (2009) 2.93
Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med (2006) 2.80
Inhalation anthrax. Ann N Y Acad Sci (1980) 2.66
Anthrax as a potential biological warfare agent. Arch Intern Med (1998) 2.40
Bacillus anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model. J Infect Dis (2007) 2.01
Inhalational anthrax: epidemiology, diagnosis, and management. Chest (1999) 1.97
Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats. Am J Physiol Regul Integr Comp Physiol (2004) 1.97
Fluid support worsens outcome and negates the benefit of protective antigen-directed monoclonal antibody in a lethal toxin-infused rat Bacillus anthracis shock model. Crit Care Med (2007) 1.63
Anthrax meningoencephalitis. Neurology (2002) 1.60
Norepinephrine increases blood pressure but not survival with anthrax lethal toxin in rats. Crit Care Med (2009) 1.60
Injectional anthrax in a heroin skin-popper. Lancet (2000) 1.58
A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis (2007) 1.51
Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis. J Infect Dis (2004) 1.51
Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun (2007) 1.40
Anthrax infection. Am J Respir Crit Care Med (2011) 1.39
Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect Immun (2006) 1.38
An outbreak of infection with Bacillus anthracis in injecting drug users in Scotland. Euro Surveill (2010) 1.24
Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect Immun (2009) 1.22
Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model. Hum Antibodies (2003) 1.20
An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin. Infect Immun (2005) 1.20
Cutaneous complications of intravenous drug abuse. Br J Dermatol (2004) 1.20
Survival of a patient with intestinal anthrax. Am J Med (1977) 1.20
Anthrax lethal and edema toxins produce different patterns of cardiovascular and renal dysfunction and synergistically decrease survival in canines. J Infect Dis (2010) 1.19
Anthrax. Pathol Annu (1971) 1.19
Molecular cloning and expression of the Bacillus anthracis edema factor toxin gene: a calmodulin-dependent adenylate cyclase. J Bacteriol (1988) 1.18
Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci U S A (2006) 1.18
Management of anthrax meningitis. Lancet Infect Dis (2005) 1.17
Investigations and control measures following a case of inhalation anthrax in East London in a drum maker and drummer, October 2008. Euro Surveill (2008) 1.16
Tackling anthrax. Nature (2001) 1.16
Anthrax lethal factor represses glucocorticoid and progesterone receptor activity. Proc Natl Acad Sci U S A (2003) 1.16
Anthrax infection in drug users. Lancet (2010) 1.15
Inhalation anthrax associated with dried animal hides--Pennsylvania and New York City, 2006. MMWR Morb Mortal Wkly Rep (2006) 1.15
Outbreak of oral-oropharyngeal anthrax: an unusual manifestation of human infection with Bacillus anthracis. Am J Trop Med Hyg (1984) 1.15
Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor binding. Proc Natl Acad Sci U S A (2009) 1.14
A review of cutaneous anthrax and its outcome. J Infect Public Health (2010) 1.13
Radiological changes in inhalation anthrax. A report of radiological and pathological correlation in two cases. Clin Radiol (1975) 1.12
Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapy. Am J Respir Crit Care Med (2006) 1.08
Characterization of the human immune response to the UK anthrax vaccine. FEMS Immunol Med Microbiol (2004) 1.08
Human monoclonal antibodies that neutralize anthrax toxin by inhibiting heptamer assembly. Hum Antibodies (2004) 1.07
Human-derived, plant-produced monoclonal antibody for the treatment of anthrax. Vaccine (2005) 1.05
In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity. J Antimicrob Chemother (2003) 1.02
Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep (2002) 1.00
A case of septicaemic anthrax in an intravenous drug user. BMC Infect Dis (2011) 0.99
Anthrax edema toxin has cAMP-mediated stimulatory effects and high-dose lethal toxin has depressant effects in an isolated perfused rat heart model. Am J Physiol Heart Circ Physiol (2011) 0.98
Probable human anthrax death in Scotland. Euro Surveill (2006) 0.98
Conference report on public health and clinical guidelines for anthrax. Emerg Infect Dis (2008) 0.98
Subcutaneous anthrax in three intravenous drug users: a new clinical diagnosis. J Bone Joint Surg Br (2011) 0.97
Corticosteroid in treatment of malignant edema of chest wall and neck (anthrax). Dis Chest (1968) 0.97
Preliminary case report of fatal anthrax in an injecting drug user in North-Rhine-Westphalia, Germany, December 2009. Euro Surveill (2010) 0.96
Case records of the Massachusetts General Hospital. Case 25-2010. A 24-year-old woman with abdominal pain and shock. N Engl J Med (2010) 0.95
Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines. J Infect Dis (2012) 0.92
An unusual case of peritonitis in an intravenous drug user. Gastroenterology (2011) 0.91
Current and future medical approaches to combat the anthrax threat. J Med Chem (2010) 0.90
Cutaneous anthrax: a concise review. Cutis (2002) 0.89
The potential contributions of lethal and edema toxins to the pathogenesis of anthrax associated shock. Toxins (Basel) (2011) 0.88
Inhalational anthrax: radiologic and pathologic findings in two cases. AJR Am J Roentgenol (2003) 0.87
Intestinal anthrax in a two-year-old child. Pediatr Infect Dis J (1995) 0.87
Anthrax in a Scottish intravenous drug user. J Forensic Leg Med (2010) 0.87
Injection anthrax causing compartment syndrome and necrotising fasciitis. J Clin Pathol (2010) 0.87
The surgical management of injectional anthrax. J Plast Reconstr Aesthet Surg (2010) 0.87
The inhibition of the interaction between the anthrax toxin and its cellular receptor by an anti-receptor monoclonal antibody. Biochem Biophys Res Commun (2009) 0.83
Extraordinary case report: cutaneous anthrax. Am J Dermatopathol (1997) 0.82
A human antibody against anthrax protective antigen protects rabbits from lethal infection with aerosolized spores. Hum Antibodies (2007) 0.82
Anthrax: from antiquity and obscurity to a front-runner in bioterrorism. Infect Dis Clin North Am (2006) 0.81
Primary anthrax presenting as an injection "abscess". Indian J Pathol Microbiol (1988) 0.80
Anthrax vaccine. Med Lett Drugs Ther (1998) 0.79
EXPERIMENTAL SUBCUTANEOUS ANTHRAX IN CHIMPANZEES. Exp Mol Pathol (1964) 0.78
Cutaneous anthrax. Cutis (1987) 0.77
Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature (2012) 18.23
The Genome sequence of the SARS-associated coronavirus. Science (2003) 16.68
Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA (2003) 16.08
Genome-wide association study of 107 phenotypes in Arabidopsis thaliana inbred lines. Nature (2010) 10.66
Meta-analysis of acute lung injury and acute respiratory distress syndrome trials testing low tidal volumes. Am J Respir Crit Care Med (2002) 10.52
Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature (2007) 10.40
Modelling schizophrenia using human induced pluripotent stem cells. Nature (2011) 7.41
A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci U S A (2012) 6.27
Trends in survival after in-hospital cardiac arrest. N Engl J Med (2012) 5.67
Characterization of human metapneumoviruses isolated from patients in North America. J Infect Dis (2002) 5.64
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med (2003) 5.45
Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med (2004) 5.23
Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet (2007) 5.21
A high-resolution map of the three-dimensional chromatin interactome in human cells. Nature (2013) 5.18
Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science (2006) 4.71
Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis (2004) 4.29
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol (2011) 4.16
New world bats harbor diverse influenza A viruses. PLoS Pathog (2013) 4.10
Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol (2013) 3.90
Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell (2005) 3.89
Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. PLoS Med (2010) 3.85
Long-term outcomes in elderly survivors of in-hospital cardiac arrest. N Engl J Med (2013) 3.85
Epigenomic analysis of multilineage differentiation of human embryonic stem cells. Cell (2013) 3.81
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol (2003) 3.51
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
AMPylation of Rho GTPases by Vibrio VopS disrupts effector binding and downstream signaling. Science (2008) 3.44
Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin Outcome Study. Hypertension (2006) 3.42
Human Bocavirus infection, Canada. Emerg Infect Dis (2006) 3.30
Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther (2007) 3.26
Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature (2004) 3.24
A Pseudomonas syringae effector inactivates MAPKs to suppress PAMP-induced immunity in plants. Cell Host Microbe (2007) 3.15
The scale of population structure in Arabidopsis thaliana. PLoS Genet (2010) 3.12
PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J Cell Biol (2014) 3.12
Triple reassortant H3N2 influenza A viruses, Canada, 2005. Emerg Infect Dis (2006) 3.05
Label-free, normalized quantification of complex mass spectrometry data for proteomic analysis. Nat Biotechnol (2009) 3.01
Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature (2013) 3.00
Identification of a novel astrovirus (astrovirus VA1) associated with an outbreak of acute gastroenteritis. J Virol (2009) 2.96
Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med (2002) 2.95
Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol (2012) 2.91
Novel avian influenza H7N3 strain outbreak, British Columbia. Emerg Infect Dis (2004) 2.90
Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension (2013) 2.89
Pseudomonas syringae effector AvrPto blocks innate immunity by targeting receptor kinases. Curr Biol (2007) 2.84
Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell (2008) 2.84
Anterior chamber width measurement by high-speed optical coherence tomography. Ophthalmology (2005) 2.77
Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med (2013) 2.70
Susceptibility to neurodegeneration in a glaucoma is modified by Bax gene dosage. PLoS Genet (2005) 2.68
Progressive ganglion cell loss and optic nerve degeneration in DBA/2J mice is variable and asymmetric. BMC Neurosci (2006) 2.68
Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension (2010) 2.64
Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med (2010) 2.62
Transcriptome characterization elucidates signaling networks that control human ES cell growth and differentiation. Nat Biotechnol (2004) 2.60
Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. Lancet Neurol (2010) 2.60
Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis (2009) 2.59
Bundled care for septic shock: an analysis of clinical trials. Crit Care Med (2010) 2.57
A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol (2003) 2.50
Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ (2011) 2.50
Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol (2011) 2.50
Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med (2002) 2.47
miR-301a as an NF-κB activator in pancreatic cancer cells. EMBO J (2010) 2.47
A coastal cline in sodium accumulation in Arabidopsis thaliana is driven by natural variation of the sodium transporter AtHKT1;1. PLoS Genet (2010) 2.45
Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. Hypertension (2007) 2.43
Two calcium-dependent protein kinases, CPK4 and CPK11, regulate abscisic acid signal transduction in Arabidopsis. Plant Cell (2007) 2.40
Genome sequencing and comparison of two nonhuman primate animal models, the cynomolgus and Chinese rhesus macaques. Nat Biotechnol (2011) 2.37
Ambulatory blood pressure monitoring in 9357 subjects from 11 populations highlights missed opportunities for cardiovascular prevention in women. Hypertension (2011) 2.33
beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell (2002) 2.33
Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol (2002) 2.31
Pathogenesis of avian influenza (H7) virus infection in mice and ferrets: enhanced virulence of Eurasian H7N7 viruses isolated from humans. J Virol (2007) 2.30
Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens (2010) 2.28
A transforming metal nanocomposite with large elastic strain, low modulus, and high strength. Science (2013) 2.28
A cross-sectional study of the microeconomic impact of cardiovascular disease hospitalization in four low- and middle-income countries. PLoS One (2011) 2.23
Positional cloning of the murine flavivirus resistance gene. Proc Natl Acad Sci U S A (2002) 2.22
Substantia nigra tangles are related to gait impairment in older persons. Ann Neurol (2006) 2.17
CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. J Clin Invest (2010) 2.15
Role of health insurance in averting economic hardship in families after acute stroke in China. Stroke (2009) 2.13
Treatment of long-lasting persistent atrial fibrillation using minimally invasive surgery combined with irbesartan. Ann Thorac Surg (2011) 2.11
Sensitive and broadly reactive reverse transcription-PCR assays to detect novel paramyxoviruses. J Clin Microbiol (2008) 2.10
Seizure-associated, aberrant neurogenesis in adult rats characterized with retrovirus-mediated cell labeling. J Neurosci (2007) 2.09
Comparative assessment of scoring functions on a diverse test set. J Chem Inf Model (2009) 2.09
Predictive role of the nighttime blood pressure. Hypertension (2010) 2.07
Potential bridges for HIV infection to men who have sex with men in Guangzhou, China. AIDS Behav (2006) 2.06
Urinary angiotensinogen excretion and ambulatory blood pressure. J Hypertens (2012) 2.04
The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol (2010) 2.04
Separating practice guidelines from pharmaceutical marketing. Crit Care Med (2007) 2.03
Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. J Infect Dis (2005) 2.03
Crop diversity for yield increase. PLoS One (2009) 2.02
High-speed optical coherence tomography of corneal opacities. Ophthalmology (2007) 2.02
Bacillus anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model. J Infect Dis (2007) 2.01
Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis (2006) 1.99
Increasing evidence that the risks of rhAPC may outweigh its benefits. Intensive Care Med (2007) 1.97
Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats. Am J Physiol Regul Integr Comp Physiol (2004) 1.97
Heterozygous deletion of mitotic arrest-deficient protein 1 (MAD1) increases the incidence of tumors in mice. Cancer Res (2007) 1.96
Practice misalignments in randomized controlled trials: Identification, impact, and potential solutions. Anesth Analg (2010) 1.96
Sequence analysis of the N, P, M and F genes of Canadian human metapneumovirus strains. Virus Res (2003) 1.96
Human coronavirus NL63 infection in Canada. J Infect Dis (2005) 1.93